Navigation Links
ETEX Announces Supply Agreement with AlloSource
Date:4/24/2008

CAMBRIDGE, Mass., April 24 /PRNewswire/ ETEX Corporation, an advanced biomaterials company, announced today that it has entered into a supply agreement with AlloSource.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080424/NETH117LOGO )

AlloSource will provide ETEX with Demineralized Bone Matrix (DBM) powder to be mixed with ETEX's proprietary, nanocrystalline, fast setting calcium phosphate to form EquivaBone(TM).

This agreement is consistent with ETEX's multi-source tissue acquisition strategy, allowing ETEX to address the market demand for an osteoinductive DBM product that is designed to flow and set hard once implanted. ETEX will manufacture EquivaBone(TM) in its Cambridge facilities and market the product through its newly formed direct distribution channel.

Brian Ennis, CEO of ETEX Corporation, states "ETEX is pleased to form a partnership with AlloSource and we look forward to a long relationship. We are impressed with the capabilities, service levels, and commitment to excellence that AlloSource provides."

About ETEX Corporation

Established in 1989, ETEX Corporation develops, manufactures and commercializes calcium phosphate-based biomaterials for improved orthopedic clinical outcomes. A leader in bioresorbable bone substitute materials, ETEX focuses on expanding applications through combinations with cells, biologics, or therapeutic agents delivered in minimally invasive and easy to use systems. For more information, visit http://www.etexcorp.com.

About AlloSource

Founded in 1994, AlloSource, of Centennial, Colorado is one of the nation's largest non-profit providers of bone and soft tissue allografts for use in a host of medical treatments. Honoring the gift of donation, AlloSource responsibly develops, processes and distributes life-saving and life-enhancing human tissue for our communities. For more information, go to http://www.allosource.org.


'/>"/>
SOURCE ETEX Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... NC (PRWEB) , ... January 16, 2017 , ... ... company, received the prestigious Tibbetts Award from the U.S. Small Business Administration. ... “that have created a significant economic or social impact […] and are considered the ...
(Date:1/13/2017)... Research and Markets has announced the addition of the "Global ... ... CAGR of 16.83% during the period 2017-2021. The report ... market for 2017-2021. To calculate the market size, the report considers the ... also includes a a discussion of the key vendors operating in this ...
(Date:1/12/2017)... ... January 12, 2017 , ... Each year, Crain’s Detroit Business News ranks the ... evaluates the patent estate of a company, its impact and significance, and the likelihood ... the way in technologies that transform energy sources such as low dose X-ray and ...
(Date:1/12/2017)... 12, 2017   Protein Sciences Corporation , ... Flublok Influenza Vaccine ®, announced today that ... good safety results and induced strong neutralizing antibodies ... product is expected to advance into human clinical ... the Institute of Technology in Immunobiologicals of the ...
Breaking Biology Technology:
(Date:1/6/2017)... LA JOLLA, Calif. , Jan. 6, 2017 ... Phase 1 safety studies in healthy volunteers of ... CM4620, intended to treat acute pancreatitis. ... pancreas, is typically a mild disorder, but can ... to organ failure and sepsis, where extended hospital ...
(Date:1/3/2017)... , Jan. 3, 2017 Onitor, provider of ... of Onitor Track, an innovative biometric data-driven program designed ... this month at the 2017 Consumer Electronics Show (CES) ... In the U.S., the World Health Organization (WHO), ... two-thirds of adults who are overweight or obese. WHO ...
(Date:12/19/2016)... España y TORONTO , 19 de diciembre de ... Biologics Inc. que permitirá el desarrollo acelerado de MSC-1, un anticuerpo ... varios tipos de tumor en 2017, con múltiples sitios previstos a ... ... con objetivo en el factor inhibidor de leucemia (LIF), una citoquina ...
Breaking Biology News(10 mins):